Results 51 to 60 of about 12,288 (265)

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial [PDF]

, 2022
BACKGROUND: The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac® is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in ...
, Abarca, Katia, Acevedo, Mónica L, Andrade, Catalina A, Berrios, Roslye V, Bueno, Susan M, Duarte, Luisa F, Fasce, Rodrigo, Fernández, Jorge, Gaete-Argel, Aracelly, Goldblatt, David, González, Liliana A, González, Pablo A, González-Aramundiz, José V, Grifoni, Alba, Gálvez, Nicolás MS, Hoppe-Elsholz, Guillermo, Iturriaga, Carolina, Johnson, Marina, Kalergis, Alexis M, Melo-González, Felipe, Meng, Weining, Mora, Judith, Moreno-Tapia, Daniela, Navarrete, María S, Pacheco, Gaspar A, Ramírez, Eugenio, Rivera-Pérez, Daniela, Rojas, Álvaro, Ríos, Mariana, Schultz, Bárbara M, Sette, Alessandro, Soto, Jorge A, Soto-Rifo, Ricardo, Urzua, Marcela, Valiente-Echeverría, Fernando, Vallejos, Omar P, Vázquez, Yaneisi, Weiskopf, Daniela, Zeng, Gang   +39 more
core   +1 more source

The Early-Term Adverse Effects in Healthcare Personnel after CoronaVac Vaccination

Journal of Contemporary Medicine, 2022
Objectives: Among the various Covidien-19 vaccine, Sinovac vaccination program in Turkey is carried out by coronavac vaccine developed by Chinese firms.
Mehmet Kabak, Barış Çil
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Human Vaccines & Immunotherapeutics, 2023
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul   +9 more
doaj   +1 more source

Retinal artery occlusion following CoronaVac injection in a 45-year-old Filipino

GMS Ophthalmology Cases, 2023
Background: While complex public health challenges and the emergence of variants have impeded responses to the COVID pandemic, vaccines continue to represent a crucial tool in mitigating the risk of morbidity and mortality.
Mendoza, Daniel Jose M., Chan, David Francis F., Yu-Keh, Ellen N., Sy, Bryan Christopher W.   +3 more
doaj   +1 more source

Adverse events following immunization of elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil: an active surveillance study [PDF]

, 2022
Healthcare workers, the elderly and other vulnerable populations were the first to receive COVID-19 vaccines in public health programs. There were few vaccine safety data available on the elderly.
Higa-Taniguchi, Keila Tomoko, Hiratsuka, Marcel, Itto, Lucas Yuji Umesaki, Jacintho, Lucas Caue, Lara, Amanda Nazareth, Leonel, Fabio Campos, Lopes, Marta Heloisa, Miyaji, Karina Takesaki, Picone, Camila Melo, Rodrigues, Camila Cristina Martini, Sales, Amanda Caroline Ribeiro, Sartori, Ana Marli Christovam   +11 more
core   +3 more sources

Strength and durability of antibody responses to BNT162b2 and CoronaVac [PDF]

Vaccine, 2022
ABSTRACTWe studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults and women.
Benjamin J. Cowling, Irene O. L. Wong, Eunice Y. C. Shiu, Amber Y. T. Lai, Samuel M. S. Cheng, Sara Chaothai, Kelvin K. H. Kwan, Mario Martín-Sánchez, Leo L. M. Poon, Dennis K. M. Ip, Gabriel M. Leung, Nancy H. L. Leung, J. S. Malik Peiris   +12 more
openaire   +2 more sources

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

Human Vaccines & Immunotherapeutics, 2022
Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity.
Dandan Zhu, Yuansheng Hu, Zhiwei Jiang, Tuantuan Yang, Kai Chu, Hengming Zhang, Jialei Hu, Xing Meng, Zhijun Tan, Jingliang Wu, Xiaojuan Lian, Changgui Li, Hongxing Pan   +12 more
doaj   +1 more source

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants

Emerging Microbes and Infections, 2022
The waning humoral immunity and emerging contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants resulted in the necessity of the booster vaccination of coronavirus disease 2019 (COVID-19).
Yuxin Chen, Lin Chen, Shengxia Yin, Yue Tao, Liguo Zhu, Xin Tong, Minxin Mao, Ming Li, Yawen Wan, Jun Ni, Xiaoyun Ji, Xianchi Dong, Jie Li, Rui Huang, Ya Shen, Han Shen, Changjun Bao, Chao Wu   +17 more
doaj   +1 more source

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study [PDF]

, 2022
BACKGROUND: Bell's palsy is a rare adverse event reported in clinical trials of COVID-19 vaccines. However, to our knowledge no population-based study has assessed the association between the inactivated SARS-CoV-2 vaccines and Bell's palsy.
Chan, EWY, Chan, FLF, Chan, LST, Chui, CSL, Chung, RKC, Cowling, BJ, Fong, WC, Gao, L, Hung, IFN, Lai, FTT, Lam, ICH, Lau, AYL, Lau, KK, Lee, CK, Leung, GM, Li, X, Lo, D, Mok, VCT, Wan, EYF, Wong, I, Yan, VKC, Yu, Q   +21 more
core  

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study

Human Vaccines & Immunotherapeutics, 2023
The durability of antibody responses induced by the three-dose of CoronaVac vaccination, especially against SARS-CoV-2 Omicron subvariants, remains unclear.
Cheng Cao, Qin Guo, Yaping Dai, Junfeng Jiang, Min Liu, Tuo Ji, Pengcheng Zhou, Fang Gong   +7 more
doaj   +1 more source